Vertex Pharmaceuticals Incorporated Stock News

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 fina

The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these compani

It's always a good time to buy shares of Eli Lilly. Pfizer is undervalued and underrated.

Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one.

Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command ex

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.

Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The healthcare industry tends to do well in all types of economies. Vertex just garnered a new blockbuster approval, and more could be around the corner.

Amazon has multiple business moats and ways to continue growing. MercadoLibre is well positioned to capitalize on the massive opportunities in Latin America.

Healthcare and digital advertising are mammoth industries. Vertex is widening its moat across the rare disease drug market.

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings.

Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders.